Media Center
- No
-
Category
- Show all
- Press Release
- News Article
- PR Video
- CEO Story
- Title
- Author
- Time uploaded
- Views
- Likes
- 205
- Press Release
- Press Release PharmAbcineโs PMC-309 successfully passed Safety Review Committee for 2mg/kg Cohort in Phase 1 Trial for Advanced or Metastatic Solid Tumors
- (์ฃผ)ํ๋ฉฅ์
- 21 Aug 2025
- Views1828
- 0
- 204
- News Article
- News Article PharmAbcine to Present PMC-403 and Vascular Normalization Platform at BIO USA 2025_THE BIO
- (์ฃผ)ํ๋ฉฅ์
- 9 Jun 2025
- Views2445
- 0
- 203
- Press Release
- Press Release PharmAbcineโs PMC-309 successfully completes 1mg/kg Cohort in Phase 1 Trial for Advanced or Metastatic Solid Tumors
- (์ฃผ)ํ๋ฉฅ์
- 19 May 2025
- Views2681
- 0
- 202
- News Article
- News Article PharmAbcine and Arontier Partnership for AI-Driven Antibody-Based Drug Development Platform_THE BIO
- (์ฃผ)ํ๋ฉฅ์
- 12 Feb 2025
- Views3866
- 0
- 201
- Press Release
- Press Release PharmAbcine at JP Morgan Healthcare Conference 2025
- (์ฃผ)ํ๋ฉฅ์
- 10 Jan 2025
- Views4070
- 0
- 200
- Press Release
- Press Release PharmAbcine Announces Safety Approval for 3mg Multiple-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration
- (์ฃผ)ํ๋ฉฅ์
- 9 Jan 2025
- Views3607
- 0
- 199
- Press Release
- Press Release PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration
- PharmAbcine
- 16 Oct 2024
- Views3911
- 0
- 198
- Press Release
- Press Release PharmAbcine Announces Safety Approval for the First Dose Cohort in Phase 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors
- PharmAbcine
- 9 Jul 2024
- Views4668
- 0
- 197
- Press Release
- Press Release PharmAbcineโs Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg
- PharmAbcine
- 2 Jul 2024
- Views4225
- 0
- 196
- Press Release
- Press Release PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024
- PharmAbcine
- 23 May 2024
- Views4604
- 0
